Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and opc-67683

levofloxacin has been researched along with opc-67683 in 4 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(opc-67683)		Trials
(opc-67683)		Recent Studies (post-2010) (opc-67683)
4,3465812,20924017225

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Mabhula, A; Singh, V1
Jeong, BH; Koh, WJ; Kwon, YS1
Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ1
Ahn, JH; Cho, SN; Hahn, S; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, DK; Kim, J; Kim, JS; Kim, K; Kim, S; Kim, SY; Kim, YR; Kwak, N; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Seok, KH; Shim, TS; Yim, D; Yim, JJ; Yoon, S1

Reviews

2 review(s) available for levofloxacin and opc-67683

ArticleYear
Drug-resistance in
    MedChemComm, 2019, Aug-01, Volume: 10, Issue:8

    Topics:

2019
Tuberculosis: clinical trials and new drug regimens.
    Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3

    Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant

2014

Trials

2 trial(s) available for levofloxacin and opc-67683

ArticleYear
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
    Trials, 2019, Jan-16, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult

2019
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant

2022